ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
34.68
-1.17%
US Tech 100
16,918.80
-2.26%
S&P 500
5,035.69
-1.57%
US Dollar vs CAD
1.3777
0.80%
Bitcoin
60,733.43
0.22%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Celldex Therapeutics Inc (CLDX)

  7. Celldex Therapeutics Inc (CLDX) News

CLDX Celldex Therapeutics Inc

37.42
0.42 (1.14%)
After Hours
Last Updated: 16:50:49
Delayed by 15 minutes
Share Name Share Symbol Market Stock Type
Celldex Therapeutics Inc CLDX NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
Upgrade Icon
0.42 1.14% 37.42 16:50:49
Open Price Low Price High Price Close Price Previous Close
36.74 36.35 38.15 37.42 37.00
more quote information »

Recent News

Date Time Source Heading
4/17/202407:01GLOBECelldex Announces Completion of Enrollment in Phase 2 Study..
3/08/202406:00GLOBECelldex Therapeutics to Participate in the Leerink Partners..
3/05/202409:30GLOBECelldex Therapeutics to Present at TD Cowen’s 44th Annual..
3/05/202409:10GLOBECelldex Therapeutics Announces Closing of Public Offering of..
3/01/202415:10EDGAR2Form 8-K - Current report
3/01/202415:09EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
2/29/202420:14GLOBECelldex Therapeutics Announces Pricing of Upsized $400..
2/28/202415:10EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
2/28/202415:01GLOBECelldex Therapeutics Announces Proposed Public Offering of..
2/26/202407:18EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
2/26/202406:05EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
2/26/202406:01EDGAR2Form 8-K - Current report
2/26/202406:01GLOBECelldex Reports Fourth Quarter and Year End 2023 Financial..
2/24/202413:05GLOBECelldex Therapeutics Presents Positive 12 Week Results from..
2/15/202415:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2/14/202415:17EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
2/14/202411:52EDGAR2Form SC 13G - Statement of acquisition of beneficial..
2/14/202410:48EDGAR2Form SC 13G - Statement of acquisition of beneficial..
2/14/202406:38EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
2/13/202408:41EDGAR2Form SC 13G - Statement of acquisition of beneficial..
2/08/202409:11EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
2/06/202415:01GLOBECelldex to Participate in the Guggenheim Healthcare Talks..
2/05/202407:01GLOBECelldex Announces Upcoming Presentation of Barzolvolimab..
1/04/202415:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/27/202315:15GLOBECelldex Therapeutics to Present at 6th Annual Evercore ISI..
11/20/202315:15EDGAR2Form SC 13G - Statement of acquisition of beneficial..
11/08/202316:03EDGAR2Form 8-K - Current report
11/08/202316:01EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
11/07/202322:15GLOBECelldex Therapeutics Announces Pricing of Public Offering of..
11/07/202315:01EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
11/07/202315:01GLOBECelldex Therapeutics Announces Proposed Public Offering of..
11/06/202308:00EDGAR2Form 8-K - Current report
11/06/202305:30GLOBECelldex Therapeutics Announces Positive Topline Results from..
11/05/202314:00GLOBECelldex Therapeutics Presents Positive Data from Prurigo..
11/03/202315:01EDGAR2Form S-3ASR - Automatic shelf registration statement of..
11/02/202315:06EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
11/02/202315:01EDGAR2Form 8-K - Current report
11/02/202315:01GLOBECelldex Reports Third Quarter 2023 Financial Results and..
9/26/202306:01GLOBECelldex Announces Acceptance of Abstract for Barzolvolimab..
9/25/202307:31GLOBECelldex Therapeutics to Present at Cantor Global Healthcare..
8/08/202315:06EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
8/08/202315:01EDGAR2Form 8-K - Current report
8/08/202315:01GLOBECelldex Reports Second Quarter 2023 Financial Results and..
7/11/202307:01GLOBECelldex Announces Completion of Enrollment in Phase 2 Study..
7/06/202307:01GLOBECelldex Announces First Patient Dosed in Phase 2 Study of..
6/10/202309:45GLOBECelldex Therapeutics Presents Positive Data from..
6/08/202315:01GLOBECelldex Therapeutics Announces Upcoming Barzolvolimab..
6/02/202307:01GLOBECelldex Therapeutics to Present at Jefferies Healthcare..
5/31/202307:01GLOBECelldex Announces First Patient Dosed in Phase 1 Study of..
5/15/202307:01GLOBECelldex Therapeutics Presents Positive Preclinical Data from..

Your Recent History

NASDAQ
CLDX
Celldex Therapeutics
Delayed Upgrade Clock
ADVFN Logo

Canada
Company
Business
Popular
Get The App

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved